258 related articles for article (PubMed ID: 23695514)
1. Diphtheria toxin-based targeted toxin therapy for brain tumors.
Li YM; Vallera DA; Hall WA
J Neurooncol; 2013 Sep; 114(2):155-64. PubMed ID: 23695514
[TBL] [Abstract][Full Text] [Related]
2. Targeted toxins in brain tumor therapy.
Li YM; Hall WA
Toxins (Basel); 2010 Nov; 2(11):2645-62. PubMed ID: 22069569
[TBL] [Abstract][Full Text] [Related]
3. Immunotoxin treatment of brain tumors.
Hall WA
Methods Mol Biol; 2001; 166():139-54. PubMed ID: 11217364
[No Abstract] [Full Text] [Related]
4. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
5. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
6. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
7. Clinical studies with targeted toxins in malignant glioma.
Rainov NG; Söling A
Rev Recent Clin Trials; 2006 May; 1(2):119-31. PubMed ID: 18473963
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
9. Diphtheria toxin conjugate therapy of cancer.
Frankel AE; Powell BL; Lilly MB
Cancer Chemother Biol Response Modif; 2002; 20():301-13. PubMed ID: 12703211
[TBL] [Abstract][Full Text] [Related]
10. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti CM; LeMaistre CF
Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
[No Abstract] [Full Text] [Related]
11. Immunotoxins in cancer therapy.
Kreitman RJ
Curr Opin Immunol; 1999 Oct; 11(5):570-8. PubMed ID: 10508704
[TBL] [Abstract][Full Text] [Related]
12. Targeted toxin therapy for malignant astrocytoma.
Hall WA
Neurosurgery; 2000 Mar; 46(3):544-51; discussion 552. PubMed ID: 10719849
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials of targeted toxins.
Frankel AE; Tagge EP; Willingham MC
Semin Cancer Biol; 1995 Oct; 6(5):307-17. PubMed ID: 8562908
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
Potala S; Sahoo SK; Verma RS
Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma.
Rainov NG; Gorbatyuk K; Heidecke V
Rev Recent Clin Trials; 2008 Jan; 3(1):2-9. PubMed ID: 18474010
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
17. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Mathew M; Verma RS
Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
[TBL] [Abstract][Full Text] [Related]
18. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.
Kawakami K; Nakajima O; Morishita R; Nagai R
ScientificWorldJournal; 2006 Jul; 6():781-90. PubMed ID: 16830050
[TBL] [Abstract][Full Text] [Related]
19. Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.
di Leandro L; Colasante M; Pitari G; Ippoliti R
Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133203
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins.
Kreitman RJ
Expert Opin Pharmacother; 2000 Sep; 1(6):1117-29. PubMed ID: 11249483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
